PDL BioPharma, Inc.
http://www.pdl.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PDL BioPharma, Inc.
The View From The Top: European CEOs Highlight Industry Priorities
At a high-profile panel closing out Medicines for Europe’s 30th annual conference in Dublin, six industry leaders set out their views on key topics including pricing, regulation, sustainability, and stakeholder communication.
Japan Nods Include Torii's Vtama, Skyrizi In New Uses
Japan issues approval recommendations in new indications, including Torii's Vtama in atopic dermatitis and AbbVie's Skyrizi in ulcerative colitis. Separately, filing requirements for the use of concomitant therapies have been revised.
Who’s Hired? Dr Reddy’s Names New North America Chief
A busy couple of weeks for executive appointments in the generics and biosimilars industry has seen Dr Reddy’s name a new North American CEO, Fresenius Kabi appoint a new biopharma chief, Teva recruit a new head of global operations, and more.
ANDA Suitability Petitions: The Timelines They Are A-Changin'
US suitability petition submissions see an uptick against the backdrop of GDUFA III new goals for the FDA's response to such petitions. The Pink Sheet tracks some of the activity as applicants seek to tap market opportunities without the need for new clinical data.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Eos Biotechnology, Inc.
- LENSAR, Inc.
- Noden Pharma DAC
- Noden USA
- Protein Design Labs, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice